MeSH term
Frequency | Condition_Probility | Female | 412 | 0.0 |
Humans | 1045 | 0.0 |
Pregnancy | 29 | 0.0 |
Randomized Controlled Trials | 2 | 0.0 |
Albumins/metabolism | 2 | 1.0 |
Animals | 321 | 0.0 |
DNA Adducts | 5 | 7.0 |
DNA Damage | 16 | 1.0 |
DNA Repair | 8 | 1.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
Gene Expression | 29 | 0.0 |
Amino Acid Substitution | 8 | 0.0 |
Base Pairing | 2 | 3.0 |
Mice | 112 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 624 | 0.0 |
Forecasting | 3 | 0.0 |
Adolescent | 51 | 0.0 |
Adult | 231 | 0.0 |
Biological Markers/analysis | 6 | 0.0 |
*Chromosome Aberrations | 4 | 0.0 |
Cytochrome P-450 CYP1A1/*genetics | 171 | 94.0 |
*DNA Adducts | 9 | 25.0 |
Male | 395 | 0.0 |
Polymorphism, Genetic | 109 | 2.0 |
Tobacco Smoke Pollution/*adverse effects | 4 | 12.0 |
Comparative Study | 153 | 0.0 |
Data Interpretation, Statistical | 2 | 0.0 |
Disease Progression | 4 | 0.0 |
Middle Aged | 263 | 0.0 |
Neoplasm Metastasis | 2 | 0.0 |
Retrospective Studies | 6 | 0.0 |
Software | 2 | 0.0 |
Time Factors | 38 | 0.0 |
Treatment Outcome | 3 | 0.0 |
Cells, Cultured | 86 | 0.0 |
Cytochrome P-450 Enzyme System/genetics/metabolism | 11 | 25.0 |
DNA Primers/chemistry | 12 | 1.0 |
Epoxide Hydrolases/genetics/metabolism | 4 | 66.0 |
Gene Expression Profiling | 8 | 0.0 |
Gene Expression Regulation, Enzymologic/*physiology | 3 | 3.0 |
Glutathione Transferase/genetics/metabolism | 10 | 8.0 |
Keratinocytes/cytology/*enzymology | 2 | 22.0 |
Mouth Mucosa/*cytology | 2 | 15.0 |
Oligonucleotide Array Sequence Analysis | 5 | 0.0 |
Oxidoreductases/*genetics/metabolism | 3 | 15.0 |
RNA, Messenger/metabolism | 45 | 1.0 |
Reactive Oxygen Species/*metabolism | 7 | 4.0 |
Reverse Transcriptase Polymerase Chain Reaction | 76 | 1.0 |
Xenobiotics/*metabolism | 18 | 33.0 |
Comet Assay | 4 | 5.0 |
Cytochrome P-450 CYP2E1/genetics | 15 | 39.0 |
Genotype | 198 | 2.0 |
Italy | 5 | 0.0 |
Lymphocytes/*drug effects | 2 | 4.0 |
Mutagens/*adverse effects | 3 | 50.0 |
Questionnaires | 5 | 0.0 |
Sister Chromatid Exchange | 2 | 4.0 |
Smoking | 35 | 9.0 |
Urban Health | 3 | 7.0 |
Vehicle Emissions/*adverse effects | 2 | 6.0 |
Aged | 174 | 0.0 |
Aged, 80 and over | 52 | 0.0 |
Arylamine N-Acetyltransferase/*genetics | 13 | 6.0 |
Carcinoma, Squamous Cell/enzymology/*genetics | 7 | 43.0 |
Cytochrome P-450 CYP1A1/genetics | 69 | 71.0 |
*Genetic Predisposition to Disease | 45 | 4.0 |
Glutathione Transferase/*genetics | 112 | 16.0 |
Mouth Neoplasms/enzymology/*genetics | 2 | 66.0 |
Neoplasm Proteins/*genetics | 6 | 0.0 |
*Polymorphism, Genetic | 160 | 3.0 |
Administration, Oral | 6 | 0.0 |
Biological Markers | 18 | 1.0 |
Cytochrome P-450 CYP1A1/*biosynthesis | 19 | 76.0 |
Electrophoresis, Polyacrylamide Gel | 15 | 0.0 |
Enzyme Induction | 95 | 16.0 |
Immunoblotting | 22 | 0.0 |
Microsomes, Liver/drug effects/enzymology | 17 | 17.0 |
Swine | 5 | 0.0 |
Swine, Miniature | 2 | 5.0 |
Aryl Hydrocarbon Hydroxylases/*biosynthesis/genetics | 5 | 31.0 |
Cytochrome P-450 CYP1A1/*biosynthesis/genetics | 24 | 96.0 |
*DNA-Binding Proteins | 35 | 2.0 |
Estrogen Receptor alpha | 6 | 2.0 |
Estrogen Receptor beta | 2 | 2.0 |
Polycyclic Hydrocarbons, Aromatic/*metabolism/toxicity | 2 | 100.0 |
RNA, Messenger/biosynthesis | 24 | 1.0 |
Receptors, Aryl Hydrocarbon/biosynthesis/genetics | 3 | 100.0 |
Structure-Activity Relationship | 14 | 0.0 |
Transcription Factors/biosynthesis/genetics | 3 | 4.0 |
Tumor Cells, Cultured | 141 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*genetics | 8 | 7.0 |
Smoking/adverse effects | 39 | 13.0 |
Substrate Specificity | 32 | 1.0 |
Amino Acid Motifs | 2 | 0.0 |
Amino Acid Sequence | 34 | 0.0 |
Base Sequence | 121 | 0.0 |
Cloning, Molecular | 19 | 0.0 |
Databases, Genetic | 2 | 2.0 |
Dogs | 6 | 0.0 |
Liver/enzymology | 21 | 3.0 |
Molecular Sequence Data | 110 | 0.0 |
Phylogeny | 3 | 0.0 |
RNA, Messenger/genetics/metabolism | 29 | 1.0 |
Sequence Alignment | 9 | 0.0 |
Sequence Homology, Amino Acid | 10 | 0.0 |
Species Specificity | 24 | 0.0 |
Cytochrome P-450 Enzyme System/*metabolism | 67 | 13.0 |
Drug Interactions | 21 | 1.0 |
Glucuronosyltransferase/*metabolism | 3 | 5.0 |
Glutathione Transferase/*metabolism | 5 | 15.0 |
Liver/drug effects/enzymology | 8 | 12.0 |
Mice, Inbred C57BL | 20 | 0.0 |
Oxazines/metabolism | 14 | 63.0 |
*Plant Extracts | 2 | 66.0 |
Asian Continental Ancestry Group/*genetics | 10 | 2.0 |
Breast Neoplasms/*genetics | 4 | 0.0 |
Case-Control Studies | 116 | 2.0 |
DNA Primers | 42 | 0.0 |
Japan | 21 | 1.0 |
Odds Ratio | 30 | 2.0 |
Polymerase Chain Reaction | 101 | 0.0 |
Risk Factors | 106 | 1.0 |
Enzyme Inhibitors/*pharmacology | 24 | 3.0 |
RNA, Messenger/biosynthesis/genetics/metabolism | 2 | 12.0 |
Carcinoma, Hepatocellular | 8 | 2.0 |
Cell Survival/drug effects | 16 | 1.0 |
DNA/analysis | 2 | 0.0 |
Dose-Response Relationship, Drug | 70 | 1.0 |
*Gene Expression Regulation | 8 | 0.0 |
Alleles | 64 | 0.0 |
Cytochrome P-450 CYP1A1/chemistry/*genetics | 5 | 71.0 |
DNA, Neoplasm/metabolism | 3 | 2.0 |
Incidence | 12 | 0.0 |
Japan/epidemiology | 6 | 1.0 |
Antineoplastic Agents/metabolism/*pharmacology | 2 | 7.0 |
Binding Sites | 15 | 0.0 |
Cell Division/drug effects | 22 | 0.0 |
Cytochrome P-450 CYP1A1/*biosynthesis/metabolism | 6 | 100.0 |
Cytochrome P-450 CYP1A2/*biosynthesis/metabolism | 5 | 83.0 |
DNA/drug effects/metabolism | 4 | 9.0 |
Enzyme Induction/drug effects | 72 | 19.0 |
Flavonoids/metabolism/*pharmacology | 2 | 66.0 |
Microsomes, Liver/metabolism | 15 | 8.0 |
Rats | 146 | 1.0 |
Rats, Inbred F344 | 7 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 315 | 0.0 |
Carcinoma, Squamous Cell/*genetics/mortality/pathology | 2 | 14.0 |
Cytochrome P-450 Enzyme System/*genetics | 88 | 21.0 |
DNA Mutational Analysis | 9 | 0.0 |
Disease-Free Survival | 3 | 0.0 |
English Abstract | 41 | 0.0 |
Follow-Up Studies | 3 | 0.0 |
Neoplasm Staging | 4 | 0.0 |
Polymorphism, Genetic/*genetics | 35 | 2.0 |
Prognosis | 10 | 0.0 |
Survival Rate | 7 | 0.0 |
Biotransformation | 67 | 12.0 |
Chromatography, High Pressure Liquid | 40 | 2.0 |
Isoenzymes/metabolism | 22 | 4.0 |
Microsomes, Liver/*enzymology | 21 | 10.0 |
Rabbits | 30 | 0.0 |
Rats, Sprague-Dawley | 44 | 1.0 |
Recombinant Proteins/metabolism | 26 | 1.0 |
Stereoisomerism | 7 | 1.0 |
Body Burden | 3 | 16.0 |
Cytochrome P-450 CYP1A1/analysis/*biosynthesis | 2 | 100.0 |
Diet | 5 | 1.0 |
*Environmental Exposure | 4 | 5.0 |
Epidemiologic Studies | 2 | 4.0 |
Placenta/drug effects/*enzymology | 2 | 50.0 |
Quebec/epidemiology | 3 | 10.0 |
Cytochrome P-450 Enzyme System/analysis/*biosynthesis | 2 | 66.0 |
Neoplasms/*metabolism | 2 | 2.0 |
Oxidation-Reduction | 32 | 2.0 |
Gene Expression Regulation/*drug effects | 6 | 0.0 |
Hepatocytes/*drug effects/metabolism | 2 | 18.0 |
*Nuclear Proteins | 2 | 0.0 |
Receptors, Aryl Hydrocarbon/biosynthesis | 5 | 100.0 |
Transcription Factors/*genetics/metabolism | 2 | 0.0 |
Cytochrome P-450 Enzyme System/genetics/*metabolism | 32 | 21.0 |
Enzyme Induction/genetics | 5 | 31.0 |
Hepatocytes/*enzymology | 3 | 20.0 |
Omeprazole/pharmacology | 2 | 16.0 |
RNA, Messenger/*analysis | 5 | 1.0 |
Rifampin/pharmacology | 5 | 8.0 |
Sensitivity and Specificity | 14 | 0.0 |
Occupational Exposure/*adverse effects | 9 | 9.0 |
Oxidoreductases/*genetics | 4 | 4.0 |
Polymorphism, Genetic/genetics | 10 | 1.0 |
Carcinogens/metabolism | 8 | 25.0 |
Variation (Genetics) | 11 | 0.0 |
Blotting, Northern | 26 | 0.0 |
Blotting, Western | 49 | 0.0 |
CHO Cells | 3 | 0.0 |
Carcinogens/pharmacology | 5 | 5.0 |
Cell Line | 80 | 0.0 |
Chromatin/metabolism | 3 | 1.0 |
Cytochrome P-450 CYP1A1/chemistry/*metabolism | 3 | 100.0 |
DNA, Complementary/metabolism | 6 | 0.0 |
Glutathione Transferase/metabolism | 7 | 0.0 |
Hamsters | 15 | 0.0 |
Plasmids/metabolism | 3 | 0.0 |
Promoter Regions (Genetics) | 17 | 0.0 |
Protein Binding | 21 | 0.0 |
Recombinant Fusion Proteins/metabolism | 4 | 0.0 |
Transcription Factor, Sp1/*metabolism | 2 | 0.0 |
*Transcription, Genetic | 8 | 0.0 |
Lipid Peroxidation | 2 | 1.0 |
Maternal-Fetal Exchange | 4 | 3.0 |
Metabolic Detoxication, Drug | 12 | 14.0 |
Phenotype | 27 | 0.0 |
Isoenzymes/*genetics | 17 | 3.0 |
Lymphocytes/drug effects | 2 | 2.0 |
Occupational Exposure | 8 | 10.0 |
*Carcinogens | 2 | 6.0 |
Hypoxanthine Phosphoribosyltransferase/genetics | 2 | 2.0 |
Models, Chemical | 6 | 1.0 |
Mutagenicity Tests/methods | 3 | 25.0 |
Mutation | 27 | 0.0 |
Cytochrome P-450 CYP1A1/metabolism | 40 | 61.0 |
Cytochrome P-450 CYP1A2/genetics/*metabolism | 9 | 37.0 |
Cytochrome P-450 Enzyme System/metabolism | 19 | 7.0 |
Lymphoma, Lymphoblastic | 2 | 66.0 |
Models, Molecular | 2 | 0.0 |
Mutagenesis, Site-Directed | 7 | 0.0 |
Oxidoreductases/metabolism | 10 | 14.0 |
Recombinant Proteins/genetics/metabolism | 12 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 68 | 0.0 |
Cytochrome P-450 CYP1A1/*metabolism | 30 | 93.0 |
Hydroxylation/drug effects | 5 | 13.0 |
Microsomes/drug effects/enzymology | 6 | 31.0 |
Quinidine/*pharmacology | 2 | 33.0 |
*Aryl Hydrocarbon Hydroxylases | 109 | 12.0 |
Enzyme Inhibitors/*pharmacokinetics | 2 | 18.0 |
In Vitro | 49 | 0.0 |
Microsomes, Liver/enzymology/metabolism | 5 | 7.0 |
*Steroid 16-alpha-Hydroxylase | 10 | 5.0 |
Steroid Hydroxylases/*metabolism | 4 | 12.0 |
Child | 22 | 0.0 |
Enzymes/*genetics/metabolism | 4 | 44.0 |
Glutathione Transferase/genetics | 47 | 15.0 |
Homozygote | 21 | 1.0 |
Xenobiotics/metabolism | 16 | 36.0 |
Gene Expression Regulation, Enzymologic | 19 | 2.0 |
RNA, Messenger/*biosynthesis/genetics | 2 | 3.0 |
Gene Frequency | 54 | 1.0 |
Genetic Predisposition to Disease/genetics | 8 | 1.0 |
Polymorphism, Genetic/*physiology | 2 | 2.0 |
Smoking/*adverse effects | 28 | 13.0 |
Confounding Factors (Epidemiology) | 2 | 3.0 |
Linkage Disequilibrium | 6 | 0.0 |
Cytochrome P-450 CYP1A2/biosynthesis | 4 | 33.0 |
Fatty Acids, Unsaturated/pharmacology | 2 | 3.0 |
Receptors, Aryl Hydrocarbon/*metabolism | 29 | 40.0 |
Tetrachlorodibenzodioxin/pharmacology | 40 | 48.0 |
Tritium | 3 | 1.0 |
Child, Preschool | 13 | 0.0 |
Cytochrome P-450 CYP2D6/*genetics | 17 | 28.0 |
India/ethnology | 2 | 2.0 |
Infant | 10 | 0.0 |
Infant, Newborn | 17 | 0.0 |
Sex Factors | 20 | 1.0 |
Body Mass Index | 5 | 0.0 |
Catechol O-Methyltransferase/*genetics | 2 | 2.0 |
Cross-Sectional Studies | 8 | 0.0 |
Cytochrome P-450 CYP1A2/*genetics | 6 | 15.0 |
Premenopause | 2 | 2.0 |
Adenocarcinoma/*genetics | 2 | 1.0 |
Prostatic Neoplasms/*genetics | 5 | 2.0 |
Turkey | 2 | 1.0 |
Cytochrome P-450 Enzyme System/*biosynthesis | 22 | 26.0 |
Esophagus/*enzymology | 3 | 75.0 |
Microsomes/enzymology | 28 | 26.0 |
Mixed Function Oxygenases/*biosynthesis | 4 | 20.0 |
Mouth Mucosa/*enzymology | 2 | 50.0 |
Anticarcinogenic Agents/*pharmacology | 9 | 10.0 |
Caco-2 Cells | 10 | 2.0 |
Colonic Neoplasms | 3 | 2.0 |
Gene Expression Regulation, Enzymologic/drug effects | 13 | 8.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 6 | 2.0 |
Kinetics | 61 | 0.0 |
*Promoter Regions (Genetics) | 5 | 0.0 |
RNA, Messenger/genetics | 24 | 0.0 |
Rats, Wistar | 17 | 1.0 |
Receptors, Aryl Hydrocarbon/*physiology | 5 | 27.0 |
Transcription, Genetic/*drug effects | 6 | 1.0 |
Adenocarcinoma/*enzymology | 2 | 8.0 |
Benz(a)Anthracenes/toxicity | 4 | 66.0 |
Carcinogens/toxicity | 5 | 9.0 |
Cattle | 7 | 0.0 |
Cell Survival | 2 | 0.0 |
*Cookery | 2 | 11.0 |
Environmental Exposure | 8 | 5.0 |
Fishes | 2 | 2.0 |
Lung Neoplasms/*enzymology | 3 | 12.0 |
Mass Fragmentography | 9 | 4.0 |
Aniline Compounds/*pharmacology | 2 | 33.0 |
Drug Evaluation, Preclinical | 3 | 1.0 |
Thiazoles/*pharmacology | 7 | 11.0 |
Dihydroxydihydrobenzopyrenes/*metabolism | 2 | 66.0 |
Glucuronides/metabolism | 2 | 4.0 |
Glucuronosyltransferase/*biosynthesis | 2 | 20.0 |
Cytochrome P-450 Enzyme System/*analysis | 4 | 21.0 |
Immunohistochemistry | 27 | 0.0 |
Isoenzymes/*metabolism | 11 | 3.0 |
Oxidoreductases, N-Demethylating/analysis | 2 | 50.0 |
Carcinoma, Hepatocellular/*metabolism | 5 | 4.0 |
DNA Adducts/*metabolism | 14 | 30.0 |
Genetic Predisposition to Disease | 65 | 2.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Isoenzymes/genetics | 26 | 7.0 |
Liver/*metabolism | 7 | 1.0 |
Liver Neoplasms/*metabolism | 5 | 5.0 |
Polycyclic Hydrocarbons, Aromatic/*metabolism | 12 | 66.0 |
Polymorphism, Restriction Fragment Length | 51 | 2.0 |
Breast/*enzymology | 4 | 26.0 |
Breast Neoplasms/*enzymology | 4 | 6.0 |
Cytochrome P-450 CYP1A2/genetics | 3 | 27.0 |
DNA Adducts/*analysis | 10 | 22.0 |
DNA, Neoplasm/analysis | 6 | 0.0 |
NAD(P)H Dehydrogenase (Quinone)/*genetics | 5 | 7.0 |
DNA/metabolism | 13 | 0.0 |
European Continental Ancestry Group | 8 | 1.0 |
Arylamine N-Acetyltransferase/*genetics/metabolism | 6 | 11.0 |
Cytochrome P-450 Enzyme System/*genetics/metabolism | 20 | 16.0 |
Glutathione Transferase/*genetics/metabolism | 13 | 17.0 |
Leukocytes | 2 | 3.0 |
Taiwan/epidemiology | 6 | 5.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Cytochromes b5/*metabolism | 2 | 33.0 |
Escherichia coli | 3 | 0.0 |
NADPH-Ferrihemoprotein Reductase/*metabolism | 2 | 33.0 |
Recombinant Proteins/biosynthesis | 3 | 0.0 |
Xenobiotics/*pharmacology | 5 | 17.0 |
Tumor Cells, Cultured/drug effects/metabolism | 3 | 1.0 |
Catalysis/drug effects | 3 | 15.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*chemistry | 2 | 40.0 |
Acetyltransferases/*genetics | 4 | 7.0 |
DNA Repair/*genetics | 3 | 0.0 |
Disease Susceptibility | 27 | 3.0 |
Cell Division | 7 | 0.0 |
Environmental Pollutants/*toxicity | 8 | 21.0 |
Enzyme Activation/drug effects | 9 | 0.0 |
Receptors, Aryl Hydrocarbon/metabolism | 15 | 38.0 |
Tetrachlorodibenzodioxin/*toxicity | 22 | 45.0 |
Transcription Factors/metabolism | 10 | 0.0 |
Antibiotics, Antineoplastic/*pharmacology | 2 | 1.0 |
Cytochrome P-450 CYP1A1/*biosynthesis/pharmacology | 2 | 100.0 |
Drug Screening Assays, Antitumor | 5 | 1.0 |
Mice, Nude | 3 | 0.0 |
Neoplasms, Experimental | 2 | 5.0 |
Cytochrome P-450 Enzyme System/biosynthesis/genetics | 3 | 21.0 |
*Environment | 2 | 4.0 |
Gene Expression Regulation, Neoplastic | 11 | 0.0 |
Glutathione Transferase/biosynthesis/genetics | 3 | 21.0 |
Lung Neoplasms/enzymology/*genetics | 8 | 22.0 |
Multivariate Analysis | 8 | 0.0 |
RNA, Messenger/biosynthesis/*genetics | 2 | 8.0 |
Aryl Hydrocarbon Hydroxylases/genetics/*metabolism | 4 | 16.0 |
Cytochrome P-450 CYP1A1/genetics/metabolism | 23 | 76.0 |
Cytochrome P-450 CYP1A2/genetics/metabolism | 6 | 35.0 |
Prostatectomy | 2 | 2.0 |
RNA, Messenger | 2 | 0.0 |
Age of Onset | 5 | 0.0 |
*Biological Markers | 2 | 1.0 |
Flow Cytometry | 3 | 0.0 |
DNA-Binding Proteins/*genetics | 3 | 0.0 |
Environmental Pollutants/*poisoning | 2 | 22.0 |
Haplotypes | 5 | 0.0 |
Receptors, Aryl Hydrocarbon/*genetics | 12 | 38.0 |
Age Factors | 17 | 0.0 |
Benzo(a)pyrene/pharmacology | 11 | 52.0 |
Breast/metabolism | 2 | 2.0 |
Carcinogens | 4 | 5.0 |
Linear Models | 5 | 1.0 |
Carcinoma, Squamous Cell/genetics | 6 | 11.0 |
Esophageal Neoplasms/*genetics | 3 | 4.0 |
Genetic Predisposition to Disease/*genetics | 5 | 1.0 |
Cohort Studies | 8 | 0.0 |
Genes, p53/*genetics | 6 | 1.0 |
*Hydrocarbons, Chlorinated | 2 | 15.0 |
DNA Adducts/analysis | 3 | 23.0 |
Enzymes/*genetics | 6 | 14.0 |
Epoxide Hydrolases/genetics | 7 | 53.0 |
Lymphocytes | 2 | 1.0 |
Mutagenicity Tests | 20 | 12.0 |
Risk | 15 | 1.0 |
Cytochrome P-450 CYP1A1/*antagonists & inhibitors/biosynthesis | 3 | 100.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors | 2 | 4.0 |
Microsomes, Liver/enzymology/*metabolism | 10 | 12.0 |
Theophylline/*analogs & derivatives/pharmacology | 2 | 18.0 |
Benzo(a)pyrene/*toxicity | 4 | 30.0 |
Breast Neoplasms | 9 | 3.0 |
Cytochrome P-450 CYP1A1/*biosynthesis/genetics/metabolism | 2 | 100.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics/metabolism | 8 | 53.0 |
Estradiol/metabolism | 4 | 4.0 |
Hydroxylation | 34 | 9.0 |
Mixed Function Oxygenases/metabolism | 10 | 7.0 |
Receptors, Aryl Hydrocarbon/agonists | 2 | 50.0 |
Receptors, Estrogen/metabolism | 6 | 2.0 |
Cytochrome P-450 CYP1A1/genetics/*metabolism | 21 | 80.0 |
Environmental Pollutants/pharmacology | 3 | 25.0 |
Gene Expression Regulation, Enzymologic/*drug effects | 16 | 10.0 |
Nicotine/pharmacology | 2 | 22.0 |
Pyridines/pharmacology | 2 | 0.0 |
China/epidemiology | 6 | 3.0 |
Esophageal Neoplasms/*epidemiology/*genetics | 2 | 100.0 |
Gene Deletion | 4 | 0.0 |
*Incineration | 2 | 66.0 |
Inhalation Exposure | 2 | 9.0 |
Korea | 4 | 1.0 |
*Occupational Exposure | 16 | 11.0 |
Regression Analysis | 19 | 1.0 |
Statistics | 2 | 0.0 |
Electrophoretic Mobility Shift Assay | 4 | 0.0 |
Enzyme Inhibitors/pharmacology | 35 | 1.0 |
Hela Cells | 4 | 0.0 |
Precipitin Tests | 4 | 0.0 |
Transcription Factors/*metabolism | 10 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*biosynthesis | 6 | 37.0 |
Epithelial Cells/enzymology | 5 | 14.0 |
Lung/*enzymology | 14 | 21.0 |
Lung Neoplasms/enzymology | 2 | 15.0 |
Smoking/*metabolism | 5 | 12.0 |
China/ethnology | 2 | 1.0 |
Cookery | 4 | 7.0 |
Binding, Competitive | 10 | 0.0 |
Enzyme Activation | 9 | 0.0 |
Promoter Regions (Genetics)/drug effects | 6 | 4.0 |
Protein Conformation | 3 | 0.0 |
Trans-Activation (Genetics)/*drug effects | 2 | 2.0 |
Dimerization | 2 | 0.0 |
Ligands | 12 | 0.0 |
Transfection | 54 | 0.0 |
DNA/genetics | 8 | 0.0 |
Parkinson Disease/*genetics | 3 | 3.0 |
Cytochrome P-450 CYP1A2/*metabolism | 8 | 10.0 |
Mutagens/metabolism | 5 | 18.0 |
Logistic Models | 15 | 2.0 |
Benzo(a)pyrene/*metabolism/toxicity | 3 | 75.0 |
Carcinogens/*metabolism/toxicity | 5 | 31.0 |
Down-Regulation | 11 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 7 | 1.0 |
Receptors, Aryl Hydrocarbon/metabolism/*physiology | 2 | 50.0 |
Tetrachlorodibenzodioxin/toxicity | 8 | 38.0 |
Cytochrome P-450 Enzyme System/drug effects/*genetics/metabolism | 2 | 100.0 |
Mutagenicity Tests/*methods | 4 | 15.0 |
Recombinant Proteins/drug effects/genetics/metabolism | 3 | 18.0 |
Tobacco | 5 | 17.0 |
Coumarins/metabolism | 3 | 12.0 |
Cytochrome P-450 CYP2D6 | 8 | 10.0 |
Ethanolamines/metabolism | 4 | 22.0 |
Mixed Function Oxygenases/genetics | 5 | 13.0 |
NADP/metabolism | 5 | 4.0 |
NADPH-Ferrihemoprotein Reductase/*genetics/metabolism | 4 | 80.0 |
Nitrosamines/toxicity | 2 | 40.0 |
Salmonella typhimurium/*genetics | 3 | 42.0 |
Steroid Hydroxylases/genetics | 3 | 11.0 |
Cytochrome P-450 CYP1A1/*antagonists & inhibitors/genetics/metabolism | 6 | 100.0 |
Microsomes, Liver/drug effects/metabolism | 5 | 10.0 |
Quinine/pharmacology | 3 | 23.0 |
Recombinant Proteins/antagonists & inhibitors/genetics/metabolism | 3 | 10.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors/metabolism | 2 | 15.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*metabolism | 12 | 9.0 |
Isoenzymes/antagonists & inhibitors/metabolism | 6 | 8.0 |
Antioxidants/*pharmacology | 3 | 2.0 |
*Biflavonoids | 2 | 20.0 |
DNA Damage/*drug effects | 7 | 15.0 |
*Flavonoids | 3 | 13.0 |
Liver/cytology/drug effects/metabolism | 2 | 16.0 |
Oxidative Stress/*drug effects | 2 | 5.0 |
Phenols/*pharmacology | 3 | 8.0 |
Polymers/*pharmacology | 3 | 18.0 |
Tea/*chemistry | 2 | 12.0 |
DNA Adducts/drug effects | 2 | 50.0 |
Microsomes/*drug effects/enzymology | 2 | 66.0 |
Plasmids | 7 | 0.0 |
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide/analysis | 2 | 50.0 |
Biotransformation/drug effects | 7 | 24.0 |
Cricetulus | 4 | 0.0 |
Flavonoids/*pharmacology | 7 | 8.0 |
Liver/chemistry/drug effects | 2 | 100.0 |
Quercetin/*pharmacology | 2 | 8.0 |
Antineoplastic Agents/*pharmacology | 7 | 0.0 |
Cytochrome P-450 CYP1A1/biosynthesis/genetics | 15 | 93.0 |
Transcription, Genetic/drug effects | 18 | 2.0 |
Antineoplastic Agents/*pharmacokinetics | 2 | 15.0 |
Cytosol/enzymology | 3 | 1.0 |
Microsomes, Liver/enzymology | 22 | 10.0 |
African Continental Ancestry Group/*genetics | 6 | 2.0 |
Cytochrome P-450 Enzyme System/genetics | 19 | 18.0 |
Databases, Factual | 2 | 0.0 |
European Continental Ancestry Group/*genetics | 8 | 2.0 |
*Gene Frequency | 4 | 0.0 |
Linkage (Genetics) | 7 | 0.0 |
Neoplasms/*genetics | 3 | 1.0 |
Cytochrome P-450 CYP1A1/biosynthesis/genetics/*metabolism | 3 | 100.0 |
Microsomes/enzymology/metabolism | 3 | 17.0 |
Subcellular Fractions | 3 | 1.0 |
3T3 Cells | 2 | 0.0 |
Culture Media | 6 | 0.0 |
Cytochrome P-450 Enzyme System/analysis/*metabolism | 2 | 28.0 |
Alkane 1-Monooxygenase | 4 | 12.0 |
Cell Culture Techniques | 5 | 1.0 |
Microsomes/metabolism | 11 | 8.0 |
Mixed Function Oxygenases/genetics/*metabolism | 2 | 4.0 |
Mass Screening/*methods | 2 | 3.0 |
Colorectal Neoplasms/*etiology/*genetics | 2 | 28.0 |
*Diet | 3 | 1.0 |
*Fruit | 2 | 18.0 |
Glutathione Transferase/*genetics/pharmacology | 2 | 18.0 |
Great Britain | 3 | 1.0 |
Endometriosis/enzymology/*genetics | 2 | 33.0 |
Glutathione Transferase/chemistry/*genetics | 3 | 25.0 |
Pedigree | 6 | 0.0 |
Tetrachlorodibenzodioxin/*pharmacology | 32 | 50.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 3 | 0.0 |
Trans-Activation (Genetics)/drug effects | 7 | 3.0 |
Transforming Growth Factor beta/*physiology | 2 | 1.0 |
Arylamine N-Acetyltransferase/genetics | 13 | 22.0 |
*Genes, ras | 3 | 1.0 |
*Mutation | 14 | 0.0 |
Pancreatic Neoplasms/*genetics | 2 | 2.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*metabolism | 4 | 16.0 |
DNA, Complementary/biosynthesis | 4 | 7.0 |
Cytochrome P-450 CYP1A1/antagonists & inhibitors/metabolism | 7 | 77.0 |
Cytochrome P-450 CYP1A2/*antagonists & inhibitors/metabolism | 2 | 18.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/metabolism | 2 | 5.0 |
Microsomes, Liver/drug effects/enzymology/metabolism | 4 | 13.0 |
Stilbenes/*pharmacology | 11 | 20.0 |
Gene Expression/drug effects | 14 | 1.0 |
HL-60 Cells | 2 | 0.0 |
RNA, Neoplasm/genetics/metabolism | 4 | 2.0 |
Receptors, Aryl Hydrocarbon/genetics | 6 | 66.0 |
Tetradecanoylphorbol Acetate/pharmacology | 4 | 0.0 |
Transcription Factors/genetics | 10 | 1.0 |
Albumins/genetics | 2 | 8.0 |
*Polymerase Chain Reaction | 4 | 1.0 |
Adenocarcinoma/enzymology/*genetics | 3 | 18.0 |
Electrophoresis | 4 | 1.0 |
Exons | 20 | 0.0 |
France | 4 | 1.0 |
Sequence Analysis, DNA | 9 | 0.0 |
Breast Neoplasms/*etiology/genetics | 2 | 25.0 |
Prospective Studies | 5 | 0.0 |
Microsomes, Liver/*metabolism | 10 | 5.0 |
Mitochondria, Liver/metabolism | 2 | 13.0 |
Phosphorylation | 2 | 0.0 |
Reactive Oxygen Species/metabolism | 5 | 1.0 |
Continental Population Groups/genetics | 6 | 7.0 |
DNA/genetics/metabolism | 3 | 0.0 |
Gene Frequency/genetics | 6 | 1.0 |
Linkage (Genetics)/genetics | 2 | 0.0 |
Mutation/genetics | 3 | 0.0 |
Receptors, Aryl Hydrocarbon/*genetics/*metabolism | 2 | 33.0 |
Carcinogens/*adverse effects | 2 | 9.0 |
Micronucleus Tests | 5 | 10.0 |
Deoxyribonuclease HpaII/genetics | 3 | 75.0 |
Endometriosis/*genetics | 3 | 17.0 |
*Linkage (Genetics) | 3 | 0.0 |
Chi-Square Distribution | 3 | 0.0 |
Cytochrome P-450 CYP2E1/*genetics | 18 | 14.0 |
Lung Neoplasms/epidemiology/*genetics | 4 | 28.0 |
Catechol O-Methyltransferase/genetics | 3 | 10.0 |
Estrogens/*metabolism | 3 | 5.0 |
Heterozygote | 16 | 0.0 |
Receptors, Estrogen/*genetics | 2 | 2.0 |
Steroid 17-alpha-Hydroxylase/genetics | 4 | 14.0 |
Taiwan | 3 | 1.0 |
Cytochrome P-450 CYP2E1/genetics/metabolism | 7 | 58.0 |
Environmental Monitoring | 3 | 7.0 |
Industry | 3 | 9.0 |
Naphthols/*urine | 3 | 60.0 |
Polycyclic Hydrocarbons, Aromatic/metabolism | 4 | 80.0 |
Pyrenes/*analysis | 3 | 50.0 |
Cell Line, Transformed | 9 | 0.0 |
Gene Expression Regulation | 5 | 0.0 |
Liver/cytology/*metabolism | 3 | 4.0 |
Oligonucleotides/metabolism | 2 | 2.0 |
Cell Cycle/drug effects | 2 | 0.0 |
Dioxins/*pharmacology | 5 | 35.0 |
Biological Markers/urine | 3 | 4.0 |
Coke/*adverse effects | 3 | 50.0 |
Metallurgy | 5 | 38.0 |
Smoking/urine | 3 | 60.0 |
Genetic Engineering | 4 | 4.0 |
Mixed Function Oxygenases/genetics/metabolism | 7 | 31.0 |
NADPH-Ferrihemoprotein Reductase/genetics/metabolism | 2 | 28.0 |
Salmonella typhimurium/drug effects/genetics | 3 | 21.0 |
Aging | 2 | 0.0 |
Cytochrome P-450 CYP1A2/metabolism | 11 | 11.0 |
Fluvoxamine/*pharmacology | 2 | 8.0 |
Isoenzymes/antagonists & inhibitors | 2 | 4.0 |
Microsomes, Liver/*enzymology/metabolism | 4 | 13.0 |
Models, Statistical | 2 | 1.0 |
Molecular Probes | 2 | 3.0 |
Phenacetin/metabolism/pharmacokinetics | 2 | 100.0 |
Gene Silencing/*drug effects | 2 | 40.0 |
RNA Processing, Post-Transcriptional | 2 | 1.0 |
RNA, Messenger/drug effects/metabolism | 4 | 2.0 |
Biological Markers/*analysis | 3 | 2.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Models, Animal | 2 | 0.0 |
Transcription, Genetic | 25 | 0.0 |
DNA, Neoplasm/genetics | 3 | 0.0 |
Electrophoresis, Agar Gel | 3 | 0.0 |
Mouth Neoplasms/*genetics | 4 | 8.0 |
Polymerase Chain Reaction/methods | 10 | 0.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics | 18 | 26.0 |
Liver/*enzymology | 12 | 2.0 |
India | 5 | 1.0 |
Cell Transformation, Neoplastic | 4 | 0.0 |
Cytochrome P-450 CYP1A2/*biosynthesis | 6 | 54.0 |
RNA, Messenger/analysis | 23 | 0.0 |
Cytochrome P-450 Enzyme System/chemistry/*metabolism | 4 | 22.0 |
Microsomes, Liver/chemistry/enzymology | 4 | 66.0 |
Steroid 16-alpha-Hydroxylase | 3 | 21.0 |
Genetic Markers | 9 | 0.0 |
United States/epidemiology | 4 | 1.0 |
COS Cells | 2 | 0.0 |
Nuclear Proteins/metabolism | 7 | 0.0 |
*Trans-Activation (Genetics) | 2 | 0.0 |
Analysis of Variance | 8 | 0.0 |
Cytochrome P-450 CYP1A1/drug effects/metabolism | 4 | 66.0 |
Cytochrome P-450 CYP1A2/drug effects/metabolism | 3 | 60.0 |
Cytochrome P-450 Enzyme System/drug effects/*metabolism | 5 | 22.0 |
Microsomes, Liver/*drug effects/enzymology | 2 | 5.0 |
Carcinoma, Squamous Cell/enzymology/epidemiology/*genetics | 3 | 50.0 |
Epoxide Hydrolases/*genetics | 8 | 25.0 |
Chromosome Aberrations | 5 | 0.0 |
Environmental Pollutants/analysis/*toxicity | 2 | 66.0 |
Hydroxysteroid Dehydrogenases/genetics/metabolism | 2 | 66.0 |
DNA Adducts/blood | 2 | 25.0 |
Polycyclic Hydrocarbons, Aromatic/*toxicity | 7 | 50.0 |
Carcinogens/*pharmacokinetics | 5 | 21.0 |
Epoxide Hydrolases/metabolism | 4 | 25.0 |
Fluorescent Antibody Technique, Indirect | 4 | 0.0 |
Liver/*immunology | 2 | 5.0 |
Mass Screening | 2 | 1.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
Epidemiology, Molecular | 8 | 8.0 |
Genetic Screening | 4 | 0.0 |
Cycloheximide/pharmacology | 4 | 0.0 |
DNA Primers/genetics | 10 | 0.0 |
Genes, Reporter | 15 | 0.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
Benzo(a)pyrene/metabolism | 9 | 50.0 |
Cytochrome P-450 CYP1A1/*genetics/metabolism | 21 | 95.0 |
*Gene Expression | 8 | 0.0 |
Genetic Vectors | 5 | 0.0 |
Mutagenesis | 5 | 0.0 |
Ethnic Groups/*genetics | 2 | 1.0 |
*Genes, p53 | 7 | 1.0 |
Neoplasms/genetics | 2 | 1.0 |
Siberia | 4 | 10.0 |
Apoptosis/*drug effects | 3 | 0.0 |
*DNA Damage | 8 | 1.0 |
*Arylamine N-Acetyltransferase | 2 | 18.0 |
*Ligases | 2 | 1.0 |
Polymorphism, Single-Stranded Conformational | 9 | 0.0 |
Proteins/*genetics | 2 | 0.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
*Ubiquitin-Protein Ligases | 2 | 0.0 |
Smoking/*genetics | 5 | 12.0 |
Educational Status | 2 | 3.0 |
Carcinogens/*metabolism | 14 | 17.0 |
Cytochrome P-450 CYP1A1/*physiology | 3 | 75.0 |
Cytochrome P-450 Enzyme System/*physiology | 6 | 10.0 |
Recombinant Proteins/pharmacology | 3 | 0.0 |
Breast Neoplasms/genetics | 2 | 0.0 |
Lung Neoplasms/genetics | 4 | 6.0 |
Cytochrome P-450 CYP1A1 | 32 | 76.0 |
Cytochrome P-450 CYP2B1/metabolism | 3 | 27.0 |
Cytochrome P-450 CYP2E1/metabolism | 5 | 11.0 |
Dexamethasone/*pharmacology | 3 | 1.0 |
Hepatectomy | 2 | 2.0 |
Liver/drug effects/*enzymology | 7 | 17.0 |
Liver Regeneration/*drug effects | 2 | 22.0 |
Steroid Hydroxylases/metabolism | 5 | 8.0 |
Cytochrome P-450 CYP1A1/drug effects/*metabolism | 2 | 66.0 |
Lung Neoplasms/etiology/*genetics | 5 | 19.0 |
Microsomes | 3 | 21.0 |
Fluorenes/metabolism | 3 | 27.0 |
Quinolines/metabolism | 3 | 27.0 |
Catalase/metabolism | 2 | 3.0 |
Iron/metabolism | 2 | 1.0 |
Cytochrome P-450 CYP1A1/*drug effects/metabolism | 4 | 100.0 |
Neoplasms/prevention & control | 3 | 37.0 |
Aryl Hydrocarbon Hydroxylases/genetics | 8 | 32.0 |
Conserved Sequence | 3 | 0.0 |
Environmental Pollutants/*pharmacology | 2 | 28.0 |
Genomics | 2 | 4.0 |
Liver/metabolism | 13 | 1.0 |
Asia/epidemiology | 2 | 12.0 |
Enzymes/genetics | 2 | 6.0 |
*Genetics, Population | 3 | 0.0 |
DNA-Binding Proteins/*metabolism | 5 | 0.0 |
Repressor Proteins/*metabolism | 2 | 1.0 |
Tretinoin/*metabolism | 6 | 13.0 |
Biopsy | 2 | 0.0 |
Lung Neoplasms/*etiology | 7 | 29.0 |
Antioxidants/pharmacology | 4 | 2.0 |
NADPH-Ferrihemoprotein Reductase/metabolism | 4 | 17.0 |
Models, Biological | 13 | 0.0 |
Receptors, Aryl Hydrocarbon/genetics/*metabolism | 8 | 30.0 |
Regulatory Sequences, Nucleic Acid | 5 | 0.0 |
Benzo(a)pyrene | 2 | 100.0 |
Carcinoma/*genetics | 3 | 2.0 |
Lung Neoplasms/*genetics | 25 | 10.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
Benz(a)Anthracenes/pharmacology | 4 | 80.0 |
Luciferases/metabolism | 4 | 0.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors/*metabolism | 3 | 23.0 |
Mixed Function Oxygenases/antagonists & inhibitors/*metabolism | 2 | 4.0 |
Molecular Structure | 6 | 0.0 |
Culture Techniques | 3 | 0.0 |
Intestines/*enzymology | 2 | 5.0 |
Polycyclic Hydrocarbons, Aromatic/analysis | 3 | 60.0 |
Breast Neoplasms/*pathology | 2 | 0.0 |
Cell Division/*drug effects | 2 | 0.0 |
Mice, Inbred Strains | 2 | 0.0 |
Receptors, Aryl Hydrocarbon/*antagonists & inhibitors | 2 | 50.0 |
Tumor Cells, Cultured/drug effects | 6 | 1.0 |
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide/metabolism | 3 | 75.0 |
Enzyme-Linked Immunosorbent Assay | 6 | 0.0 |
Lung Neoplasms/*epidemiology/*genetics | 3 | 33.0 |
*Smoking | 7 | 8.0 |
Acetyltransferases/genetics | 3 | 8.0 |
Cytochrome P-450 CYP2D6/genetics | 10 | 32.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
Breast Neoplasms/*genetics/pathology | 3 | 1.0 |
*Blood | 2 | 4.0 |
*Down-Regulation | 2 | 0.0 |
Metals/*pharmacology | 2 | 14.0 |
Polycyclic Compounds/*pharmacology | 3 | 75.0 |
Feasibility Studies | 2 | 0.0 |
Specimen Handling | 2 | 2.0 |
Cytochrome P-450 Enzyme System/*genetics/*metabolism | 6 | 12.0 |
Life Style | 4 | 3.0 |
Reference Values | 24 | 0.0 |
Chemoprevention | 2 | 4.0 |
Cell Line, Tumor | 18 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 3 | 0.0 |
Introns | 3 | 0.0 |
Polymorphism, Single Nucleotide | 4 | 0.0 |
Repressor Proteins/*genetics | 2 | 0.0 |
*Alleles | 6 | 0.0 |
Codon | 2 | 0.0 |
Head and Neck Neoplasms/enzymology/*genetics | 2 | 33.0 |
Smoking/adverse effects/genetics | 3 | 30.0 |
Estradiol/*metabolism | 6 | 9.0 |
Postmenopause | 3 | 1.0 |
Steryl-Sulfatase | 2 | 1.0 |
Antibody Specificity | 8 | 0.0 |
Warfarin/metabolism | 3 | 20.0 |
Carboxyhemoglobin/analysis | 2 | 50.0 |
Lung/metabolism | 3 | 1.0 |
Genes, Reporter/drug effects | 2 | 20.0 |
Tetrachlorodibenzodioxin/metabolism/pharmacology | 2 | 33.0 |
Transcription Factors/genetics/*metabolism | 4 | 0.0 |
Half-Life | 3 | 0.0 |
Fibroblasts/cytology/metabolism | 2 | 1.0 |
Breast Neoplasms/*enzymology/genetics | 5 | 38.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*genetics | 8 | 20.0 |
Insecticides/*toxicity | 2 | 10.0 |
Receptors, Aryl Hydrocarbon/physiology | 5 | 55.0 |
Carcinogens/pharmacokinetics | 5 | 33.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Isoenzymes/biosynthesis/genetics/metabolism | 4 | 14.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors | 7 | 5.0 |
Oxidoreductases, N-Demethylating/*antagonists & inhibitors | 2 | 6.0 |
Tissue Distribution | 8 | 0.0 |
Tritium/diagnostic use | 2 | 1.0 |
Nuclear Family | 2 | 0.0 |
Syndrome | 3 | 0.0 |
Alcohol Drinking | 4 | 3.0 |
Tumor Necrosis Factor-alpha/*genetics | 2 | 0.0 |
Chloramphenicol O-Acetyltransferase/genetics | 6 | 2.0 |
Cytochrome P-450 CYP1A1/biosynthesis/*genetics | 8 | 100.0 |
Methylcholanthrene/pharmacology | 14 | 40.0 |
RNA, Neoplasm/analysis | 3 | 1.0 |
*Life Style | 4 | 7.0 |
Pyrenes/*metabolism | 7 | 50.0 |
Embryo/cytology | 3 | 4.0 |
Mice, Transgenic | 6 | 0.0 |
*Recombination, Genetic | 2 | 0.0 |
Estrogens/*pharmacology | 2 | 2.0 |
*Gene Expression Regulation, Neoplastic | 5 | 0.0 |
Receptors, Estrogen/*physiology | 3 | 9.0 |
Lymphocyte Activation | 4 | 0.0 |
Escherichia coli/genetics | 5 | 0.0 |
Aldehyde Dehydrogenase/*genetics | 3 | 1.0 |
Signal Transduction | 13 | 0.0 |
Trans-Activation (Genetics) | 6 | 0.0 |
Up-Regulation | 2 | 0.0 |
Confidence Intervals | 8 | 2.0 |
Ovarian Neoplasms/epidemiology/*genetics | 2 | 2.0 |
Parity | 2 | 1.0 |
Risk Assessment | 14 | 1.0 |
Smoking/epidemiology | 3 | 4.0 |
Polymerase Chain Reaction/*methods | 5 | 0.0 |
France/ethnology | 2 | 5.0 |
Menopause | 2 | 0.0 |
Azacitidine/pharmacology | 2 | 4.0 |
Estradiol/pharmacology | 5 | 1.0 |
Testosterone/pharmacology | 2 | 3.0 |
Bronchi/*metabolism | 2 | 6.0 |
Gene Expression/*drug effects | 13 | 6.0 |
Callithrix | 4 | 5.0 |
Tetrachlorodibenzodioxin | 4 | 57.0 |
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide/*metabolism | 2 | 28.0 |
Glutathione Transferase/genetics/*metabolism | 2 | 14.0 |
Statistics, Nonparametric | 2 | 0.0 |
Teratogens/*toxicity | 4 | 22.0 |
Aryl Hydrocarbon Hydroxylases/metabolism | 14 | 30.0 |
Estrogen Antagonists/*pharmacology | 3 | 4.0 |
Liver Neoplasms, Experimental | 4 | 8.0 |
*Smoke | 2 | 14.0 |
Transcription Factors/physiology | 2 | 0.0 |
*Gene Expression Regulation, Enzymologic | 15 | 3.0 |
Homeostasis | 2 | 0.0 |
*Oxidative Stress | 2 | 0.0 |
*Transcription Factors | 2 | 0.0 |
Spodoptera | 4 | 1.0 |
Chloramphenicol O-Acetyltransferase/biosynthesis | 5 | 3.0 |
Oxidative Stress | 4 | 1.0 |
Restriction Mapping | 5 | 0.0 |
DNA, Complementary/genetics | 12 | 0.0 |
Finland | 2 | 0.0 |
Lung/*metabolism | 4 | 4.0 |
Estradiol/analogs & derivatives/pharmacology | 2 | 6.0 |
Estrogen Antagonists/pharmacology | 5 | 5.0 |
RNA, Messenger/drug effects | 3 | 4.0 |
Signal Transduction/drug effects | 5 | 0.0 |
Polycyclic Hydrocarbons, Aromatic/pharmacokinetics/*toxicity | 2 | 100.0 |
Protein Transport | 2 | 0.0 |
Neoplasms/*enzymology | 3 | 8.0 |
Carcinoma, Squamous Cell/enzymology/etiology/*genetics | 2 | 66.0 |
Smoking/*adverse effects/genetics | 3 | 21.0 |
Cell Count | 3 | 0.0 |
Cytochrome P-450 CYP1A1/biosynthesis | 16 | 53.0 |
Mice, Inbred DBA | 3 | 0.0 |
Organ Size/drug effects | 3 | 3.0 |
Mixed Function Oxygenases/*metabolism | 8 | 5.0 |
Spectrophotometry, Ultraviolet | 4 | 2.0 |
Testosterone/metabolism | 6 | 4.0 |
Biological Transport | 2 | 0.0 |
Carcinoma, Hepatocellular/pathology | 2 | 4.0 |
Cell Nucleus/metabolism | 6 | 0.0 |
Cytosol/metabolism | 5 | 0.0 |
Receptors, Aryl Hydrocarbon/genetics/*physiology | 3 | 60.0 |
Autoradiography | 3 | 0.0 |
Benzo(a)pyrene/*pharmacology | 6 | 60.0 |
Drug Synergism | 6 | 0.0 |
NADPH-Ferrihemoprotein Reductase/genetics/*metabolism | 3 | 30.0 |
Plants, Toxic | 6 | 15.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Tobacco/enzymology | 2 | 100.0 |
Carcinogenicity Tests/methods | 2 | 50.0 |
Disease Models, Animal | 4 | 0.0 |
Carcinogenicity Tests | 4 | 5.0 |
Drug Administration Schedule | 2 | 0.0 |
Metaplasia | 2 | 2.0 |
Tetrachlorodibenzodioxin/administration & dosage/*toxicity | 2 | 50.0 |
Genetic Predisposition to Disease/epidemiology | 5 | 5.0 |
Neoplasms/epidemiology/*genetics | 3 | 37.0 |
Meat/adverse effects | 2 | 25.0 |
Organ Specificity | 6 | 0.0 |
Sequence Deletion | 5 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Catalysis | 17 | 2.0 |
Mutagens/*toxicity | 7 | 6.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Blotting, Southern | 7 | 0.0 |
Breast Neoplasms/enzymology/*genetics | 2 | 7.0 |
Heat-Shock Proteins 70/metabolism | 2 | 3.0 |
Signal Transduction/*physiology | 4 | 0.0 |
Rats, Inbred Strains | 3 | 0.0 |
Vitamin A/*metabolism | 2 | 9.0 |
Benzoflavones/pharmacology | 15 | 30.0 |
Carcinogens, Environmental/*toxicity | 2 | 13.0 |
beta-Naphthoflavone/pharmacology | 10 | 34.0 |
Carcinoma, Hepatocellular/enzymology | 2 | 11.0 |
Guinea Pigs | 6 | 0.0 |
Liver Neoplasms/enzymology | 2 | 14.0 |
Plant Extracts/*pharmacology | 2 | 2.0 |
Alkylation | 3 | 4.0 |
Acute Disease | 3 | 0.0 |
Carcinoma, Hepatocellular/*enzymology/pathology | 2 | 16.0 |
Cytochrome P-450 CYP1A1/biosynthesis/*drug effects/genetics | 3 | 100.0 |
Isoenzymes/biosynthesis | 3 | 6.0 |
Steroid Hydroxylases/biosynthesis | 3 | 33.0 |
DNA Adducts/*blood | 3 | 27.0 |
Poland | 4 | 2.0 |
Seasons | 2 | 1.0 |
Hydroxytestosterones/metabolism | 2 | 25.0 |
Benzo(a)pyrene/pharmacokinetics | 2 | 66.0 |
Cytochrome P-450 CYP1A1/biosynthesis/genetics/metabolism | 2 | 100.0 |
Cytochrome P-450 CYP1A2/biosynthesis/genetics/metabolism | 2 | 100.0 |
Organ Culture Techniques | 5 | 1.0 |
Estrogens/biosynthesis/*metabolism | 2 | 50.0 |
Superoxide Dismutase/genetics | 3 | 3.0 |
Sulfaphenazole/pharmacology | 3 | 10.0 |
Isoenzymes/drug effects/metabolism | 2 | 13.0 |
Hydrogen Peroxide/pharmacology | 2 | 0.0 |
Nitroprusside/pharmacology | 2 | 2.0 |
Fetus | 4 | 0.0 |
Microsomes, Liver/drug effects/*metabolism | 5 | 12.0 |
Cell Line/drug effects | 4 | 8.0 |
Receptors, Aryl Hydrocarbon/drug effects/genetics/*metabolism | 2 | 66.0 |
Aryl Hydrocarbon Hydroxylases/*metabolism | 5 | 10.0 |
Carcinoma, Squamous Cell/*genetics | 8 | 4.0 |
Protein p53/genetics | 3 | 1.0 |
Mixed Function Oxygenases/biosynthesis | 4 | 28.0 |
Protein Isoforms | 3 | 0.0 |
Receptors, Aryl Hydrocarbon/*antagonists & inhibitors/physiology | 2 | 100.0 |
Dexamethasone/pharmacology | 7 | 1.0 |
Phenacetin/pharmacology | 2 | 66.0 |
Phenobarbital/pharmacology | 7 | 11.0 |
Dieldrin/toxicity | 2 | 100.0 |
Environmental Pollutants/toxicity | 2 | 18.0 |
Liver/drug effects/enzymology/metabolism | 3 | 25.0 |
Apoptosis/drug effects | 4 | 0.0 |
Mice, Knockout | 6 | 0.0 |
Polychlorinated Biphenyls/*pharmacology | 3 | 21.0 |
Sex Characteristics | 4 | 0.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
Cell Cycle/*physiology | 2 | 0.0 |
Sucrase/metabolism | 2 | 22.0 |
Prenatal Exposure Delayed Effects | 4 | 13.0 |
Cytochrome P-450 CYP2D6/metabolism | 4 | 10.0 |
Microsomes, Liver/*drug effects/*metabolism | 2 | 40.0 |
Clofibrate/pharmacology | 3 | 14.0 |
Nucleic Acid Hybridization | 5 | 0.0 |
Oxidoreductases, N-Demethylating/*metabolism | 2 | 2.0 |
RNA, Messenger/*metabolism | 5 | 0.0 |
Antibodies/pharmacology | 3 | 0.0 |
Isoenzymes/*biosynthesis | 3 | 4.0 |
Phenobarbital/*pharmacology | 2 | 11.0 |
Steroid Hydroxylases/biosynthesis/genetics | 4 | 80.0 |
Lymphocytes/drug effects/*enzymology | 2 | 28.0 |
Liver/cytology/*enzymology | 2 | 10.0 |
Survival Analysis | 2 | 0.0 |
Body Weight/drug effects | 2 | 1.0 |
Carcinogens/*toxicity | 8 | 7.0 |
Glutathione Transferase/biosynthesis | 2 | 6.0 |
*Prenatal Exposure Delayed Effects | 2 | 4.0 |
RNA/metabolism | 4 | 0.0 |
Epoxide Hydrolases/*genetics/metabolism | 3 | 42.0 |
RNA, Messenger/*biosynthesis | 6 | 2.0 |
*Fires | 2 | 50.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/metabolism | 4 | 5.0 |
Carcinoma, Hepatocellular/*enzymology | 3 | 12.0 |
Insecticides/*pharmacology | 2 | 18.0 |
Interleukin-6/pharmacology | 2 | 0.0 |
Estrogens/metabolism | 5 | 6.0 |
*Polymorphism, Single Nucleotide | 5 | 0.0 |
Steroid 17-alpha-Hydroxylase/*genetics | 2 | 6.0 |
Immunization | 3 | 0.0 |
17-Hydroxysteroid Dehydrogenases/genetics | 2 | 33.0 |
Breast Neoplasms/epidemiology/*genetics/metabolism | 3 | 100.0 |
Multigene Family | 3 | 0.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
Isoleucine/genetics | 5 | 18.0 |
Chromosomes, Human, Pair 15 | 3 | 2.0 |
*European Continental Ancestry Group | 3 | 3.0 |
*Flavanones | 3 | 12.0 |
Arylamine N-Acetyltransferase/genetics/metabolism | 4 | 26.0 |
Genes, p53 | 2 | 0.0 |
Polycyclic Compounds/toxicity | 2 | 100.0 |
African Continental Ancestry Group/genetics | 5 | 1.0 |
Cytochrome P-450 CYP1A1/*genetics/*metabolism | 3 | 100.0 |
European Continental Ancestry Group/genetics | 13 | 1.0 |
Lymphocytes/enzymology | 3 | 3.0 |
Point Mutation | 11 | 0.0 |
Receptors, Aryl Hydrocarbon/*genetics/metabolism | 6 | 54.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
Cell Nucleus/*metabolism | 4 | 0.0 |
Microsomes/*enzymology | 7 | 15.0 |
Tetrachlorodibenzodioxin/metabolism/*toxicity | 2 | 40.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Leukocytes/metabolism | 2 | 1.0 |
Fetal Blood/metabolism | 2 | 3.0 |
Benzo(a)pyrene/toxicity | 7 | 43.0 |
Environmental Pollutants/*adverse effects/blood | 2 | 66.0 |
Carcinoma, Squamous Cell/etiology/*genetics | 2 | 25.0 |
Epithelial Cells/drug effects/enzymology | 2 | 11.0 |
Tumor Cells, Cultured/enzymology | 2 | 5.0 |
Anticarcinogenic Agents/pharmacology | 2 | 7.0 |
Cytochromes b5/metabolism | 2 | 25.0 |
NADP/pharmacology | 3 | 13.0 |
Isoenzymes/genetics/metabolism | 10 | 6.0 |
Esophageal Neoplasms/etiology | 2 | 66.0 |
Lung Neoplasms/etiology | 5 | 45.0 |
Fetus/*metabolism | 2 | 2.0 |
Diazepam/metabolism | 2 | 28.0 |
Liver/cytology/drug effects/*metabolism | 2 | 10.0 |
*Metallurgy | 2 | 22.0 |
Inhibitory Concentration 50 | 3 | 1.0 |
Mixed Function Oxygenases/antagonists & inhibitors/metabolism | 2 | 10.0 |
Estrone/*metabolism | 3 | 50.0 |
*Food Habits | 2 | 9.0 |
Hypoxanthine Phosphoribosyltransferase/*genetics | 3 | 6.0 |
Proteins/genetics | 3 | 0.0 |
Neoplasms/chemically induced/genetics | 2 | 66.0 |
Food Contamination | 2 | 6.0 |
Mutation, Missense | 4 | 0.0 |
Haplorhini | 3 | 1.0 |
Amines/*metabolism | 3 | 16.0 |
Heterocyclic Compounds/*metabolism | 3 | 30.0 |
Glutathione/metabolism | 3 | 1.0 |
Receptor Cross-Talk | 2 | 5.0 |
Liver/*drug effects/enzymology | 7 | 15.0 |
Receptors, Aryl Hydrocarbon/analysis | 2 | 100.0 |
*Polymorphism, Restriction Fragment Length | 15 | 1.0 |
Variation (Genetics)/genetics | 2 | 1.0 |
Chronic Disease | 3 | 0.0 |
9,10-Dimethyl-1,2-benzanthracene/pharmacology | 3 | 37.0 |
Dehydroepiandrosterone/*pharmacology | 2 | 18.0 |
Dehydroepiandrosterone Sulfate/pharmacology | 2 | 50.0 |
RNA Processing, Post-Transcriptional/*drug effects | 2 | 25.0 |
Biliary Tract/*enzymology | 2 | 100.0 |
Gallbladder/cytology/*enzymology | 2 | 100.0 |
Liver/cytology/enzymology | 2 | 25.0 |
Oxidoreductases, N-Demethylating/genetics/metabolism | 8 | 44.0 |
Pharmaceutical Preparations/*metabolism | 11 | 12.0 |
RNA, Messenger/analysis/genetics | 2 | 0.0 |
DNA, Neoplasm/*genetics | 2 | 0.0 |
Leukocytes/drug effects/metabolism | 2 | 14.0 |
Leukoplakia/*genetics | 2 | 66.0 |
Lung Neoplasms/etiology/*genetics/metabolism | 2 | 40.0 |
*Plants, Toxic | 3 | 7.0 |
Tobacco, Smokeless/*adverse effects | 2 | 25.0 |
Tumor Markers, Biological | 5 | 1.0 |
Methylation | 6 | 1.0 |
Cytochrome P-450 CYP1A1/*analysis/genetics | 2 | 100.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Breast Neoplasms/*enzymology/pathology | 3 | 9.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Amine Oxidoreductases/genetics | 2 | 1.0 |
Genes, ras/genetics | 2 | 1.0 |
Methylenetetrahydrofolate Reductase (NADPH2) | 5 | 0.0 |
Response Elements | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 9 | 0.0 |
Teratogens/pharmacology | 4 | 40.0 |
Thiazoles/*metabolism | 3 | 23.0 |
Cross Reactions | 5 | 0.0 |
Ketoconazole/pharmacology | 6 | 6.0 |
Spodoptera/virology | 2 | 25.0 |
Alcohol Drinking/metabolism | 2 | 25.0 |
Aldehyde Dehydrogenase/genetics | 2 | 6.0 |
Menarche | 2 | 10.0 |
Receptors, Estrogen/*metabolism | 3 | 1.0 |
*Signal Transduction | 2 | 0.0 |
Cocarcinogenesis | 2 | 7.0 |
Promoter Regions (Genetics)/genetics | 4 | 0.0 |
Response Elements/genetics | 2 | 1.0 |
Antibodies/*immunology | 2 | 1.0 |
Cytochrome P-450 CYP1A1/immunology/*metabolism | 2 | 100.0 |
Spectrophotometry | 3 | 1.0 |
Smoking/adverse effects/*genetics/metabolism | 2 | 66.0 |
Polycyclic Compounds/*metabolism | 7 | 53.0 |
Lung Neoplasms/*genetics/metabolism | 4 | 10.0 |
*CCAAT-Enhancer-Binding Proteins | 2 | 1.0 |
Models, Genetic | 4 | 0.0 |
Estrogen Replacement Therapy | 2 | 4.0 |
Heterozygote Detection | 2 | 0.0 |
Isoleucine | 4 | 22.0 |
Valine | 4 | 7.0 |
7-Alkoxycoumarin O-Dealkylase/metabolism | 2 | 40.0 |
Antibodies/immunology | 3 | 0.0 |
Liver/chemistry | 2 | 2.0 |
Coal | 2 | 33.0 |
Liver Neoplasms | 5 | 1.0 |
Omeprazole/*pharmacology | 7 | 29.0 |
Quinones/pharmacology | 3 | 2.0 |
Acetylation | 3 | 0.0 |
Cytochrome P-450 Enzyme System/biosynthesis/metabolism | 2 | 25.0 |
Pharmacokinetics | 2 | 5.0 |
Chromosome Mapping | 7 | 0.0 |
Baculoviridae/genetics | 4 | 2.0 |
Dealkylation | 3 | 5.0 |
Fluvoxamine/pharmacology | 2 | 14.0 |
Lung Neoplasms/enzymology/*genetics/pathology | 3 | 37.0 |
Neoplasms, Hormone-Dependent/genetics/metabolism | 2 | 25.0 |
Receptors, Aryl Hydrocarbon/genetics/metabolism | 2 | 33.0 |
Salmonella typhimurium/metabolism | 2 | 40.0 |
Environmental Pollutants/*metabolism | 2 | 66.0 |
Actins/biosynthesis | 2 | 4.0 |
Kidney/enzymology | 2 | 1.0 |
Transcription Factors/biosynthesis | 3 | 3.0 |
Intestine, Small/cytology/*enzymology | 3 | 75.0 |
Carcinoma, Basal Cell/enzymology/*genetics | 2 | 40.0 |
*Gene Deletion | 4 | 0.0 |
Skin Neoplasms/enzymology/*genetics | 2 | 25.0 |
Cell Cycle | 3 | 0.0 |
Cytokines/biosynthesis/genetics | 2 | 3.0 |
Enzyme Inhibitors/metabolism | 3 | 1.0 |
Indoles/pharmacology | 3 | 1.0 |
Ultraviolet Rays | 2 | 0.0 |
Breast Neoplasms/genetics/*metabolism | 2 | 3.0 |
Enzymes/*metabolism | 2 | 13.0 |
Mutagens/pharmacology | 2 | 5.0 |
Cytochrome P-450 CYP2B1/biosynthesis | 2 | 40.0 |
Nifedipine/metabolism | 2 | 11.0 |
Oxidoreductases, N-Demethylating/metabolism | 2 | 3.0 |
Paclitaxel/metabolism | 2 | 25.0 |
Theophylline/metabolism | 2 | 15.0 |
Quinidine/pharmacology | 4 | 9.0 |
Theophylline/analogs & derivatives/pharmacology | 4 | 18.0 |
Carcinoma, Squamous Cell/*epidemiology/*genetics | 2 | 100.0 |
Sweden/epidemiology | 2 | 1.0 |
Hepatocytes/drug effects/*enzymology | 2 | 18.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 3 | 1.0 |
Flow Cytometry/methods | 2 | 0.0 |
Cluster Analysis | 2 | 1.0 |
Leukocytes, Mononuclear/*enzymology | 3 | 12.0 |
DNA Adducts/metabolism | 6 | 17.0 |
Receptors, Aryl Hydrocarbon/*agonists/*antagonists & inhibitors | 2 | 100.0 |
DNA/blood | 3 | 1.0 |
Exons/genetics | 7 | 0.0 |
Cytochrome P-450 CYP1A1/*analysis | 2 | 100.0 |
Russia | 2 | 2.0 |
Cell Differentiation | 7 | 0.0 |
Mucous Membrane/enzymology | 3 | 27.0 |
Mouth Neoplasms/genetics | 2 | 25.0 |
Pharyngeal Neoplasms/genetics | 2 | 28.0 |
Cytochrome P-450 Enzyme System/biosynthesis/genetics/*metabolism | 4 | 25.0 |
*Pharmacokinetics | 2 | 4.0 |
Clinical Trials | 3 | 0.0 |
Germany | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*genetics/metabolism | 4 | 11.0 |
Bladder Neoplasms/etiology | 2 | 28.0 |
Neoplasms/*etiology | 4 | 15.0 |
Deoxyribonuclease HpaII | 8 | 11.0 |
Leukocytes/*metabolism | 4 | 4.0 |
Laryngeal Neoplasms/*genetics | 3 | 17.0 |
Cytochrome P-450 CYP2E1/*genetics/metabolism | 3 | 14.0 |
Isoenzymes/*biosynthesis/genetics | 5 | 21.0 |
Breast Neoplasms/*etiology | 2 | 10.0 |
Chromatography, Gas | 2 | 2.0 |
Valine/genetics | 5 | 7.0 |
Gene Expression Regulation/drug effects | 7 | 0.0 |
Carcinoma, Hepatocellular/metabolism | 2 | 2.0 |
Liver Neoplasms, Experimental/metabolism | 3 | 15.0 |
B-Lymphocytes/metabolism | 2 | 1.0 |
Dimethyl Sulfoxide/pharmacology | 3 | 3.0 |
Epithelial Cells/drug effects/enzymology/metabolism | 2 | 33.0 |
Adenocarcinoma/genetics | 3 | 4.0 |
Carcinoma, Small Cell/genetics | 4 | 10.0 |
Cytochrome P-450 CYP2B1/genetics | 2 | 100.0 |
*Gene Expression Regulation, Enzymologic/drug effects | 3 | 6.0 |
Methoxsalen/pharmacology | 2 | 25.0 |
DNA-Binding Proteins/genetics | 3 | 0.0 |
Tetrachlorodibenzodioxin/metabolism | 5 | 45.0 |
Random Allocation | 2 | 0.0 |
Imidazoles/*metabolism | 3 | 9.0 |
Mutagens/*metabolism | 5 | 13.0 |
DNA-Binding Proteins/metabolism | 6 | 0.0 |
Dioxins/pharmacology | 3 | 33.0 |
Mouth Neoplasms/etiology/*genetics | 2 | 50.0 |
*Genotype | 5 | 2.0 |
*Point Mutation | 2 | 0.0 |
*Polymorphism, Single-Stranded Conformational | 3 | 2.0 |
Urban Population | 3 | 2.0 |
Aryl Hydrocarbon Hydroxylases/genetics/metabolism | 6 | 33.0 |
RNA, Messenger/analysis/*biosynthesis | 2 | 6.0 |
Tumor Cells, Cultured/*drug effects/enzymology | 3 | 37.0 |
Benzoflavones/*pharmacology | 3 | 42.0 |
RNA, Messenger/biosynthesis/drug effects | 3 | 5.0 |
*Cryopreservation | 2 | 3.0 |
Colonic Neoplasms/*enzymology/pathology | 2 | 16.0 |
Methylcholanthrene/*pharmacology | 5 | 62.0 |
Cytochrome P-450 CYP1A1/*biosynthesis/drug effects | 3 | 100.0 |
Intestine, Small/enzymology | 2 | 12.0 |
Liposomes | 2 | 0.0 |
Cytochrome P-450 CYP1A1/*antagonists & inhibitors | 3 | 50.0 |
Cytochrome P-450 CYP1A2/*antagonists & inhibitors | 2 | 13.0 |
Flavonoids/chemistry/*pharmacology | 2 | 15.0 |
Mixed Function Oxygenases/*genetics | 3 | 2.0 |
Deoxyribonuclease HpaII/metabolism | 2 | 15.0 |
9,10-Dimethyl-1,2-benzanthracene/metabolism | 4 | 80.0 |
Placenta/*metabolism | 3 | 1.0 |
Asian Continental Ancestry Group/genetics | 3 | 0.0 |
Chile | 3 | 5.0 |
Indians, South American/*genetics | 2 | 3.0 |
NADPH-Ferrihemoprotein Reductase | 2 | 15.0 |
Pharmaceutical Preparations/metabolism | 3 | 9.0 |
Tetrachlorodibenzodioxin/analogs & derivatives/pharmacology | 2 | 100.0 |
Receptors, Estrogen/genetics | 2 | 3.0 |
DNA, Complementary | 6 | 0.0 |
Macaca fascicularis | 6 | 2.0 |
9,10-Dimethyl-1,2-benzanthracene/pharmacokinetics | 2 | 100.0 |
Curcumin/*pharmacology | 2 | 8.0 |
Oxidation-Reduction/drug effects | 2 | 2.0 |
Isoenzymes/*genetics/*metabolism | 2 | 12.0 |
*Transfection | 2 | 0.0 |
Mixed Function Oxygenases/biosynthesis/genetics | 3 | 30.0 |
RNA/analysis | 2 | 0.0 |
Saccharomyces cerevisiae | 2 | 0.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Carcinogens/metabolism/pharmacology | 2 | 66.0 |
Methylcholanthrene/toxicity | 3 | 60.0 |
DNA Probes | 3 | 0.0 |
*Regulatory Sequences, Nucleic Acid | 6 | 1.0 |
Meat | 3 | 9.0 |
Mutagens/toxicity | 4 | 11.0 |
Quinoxalines/toxicity | 2 | 40.0 |
Oxidative Stress/drug effects | 3 | 6.0 |
Prevalence | 3 | 0.0 |
Environmental Exposure/*adverse effects | 2 | 7.0 |
Population Surveillance | 2 | 1.0 |
United States | 8 | 0.0 |
In Situ Hybridization | 3 | 0.0 |
Plasmids/genetics | 3 | 0.0 |
Saccharomyces cerevisiae/genetics | 3 | 0.0 |
beta-Galactosidase/genetics | 3 | 2.0 |
Liver/drug effects/metabolism | 3 | 4.0 |
Isoenzymes/biosynthesis/*metabolism | 2 | 22.0 |
Helix-Loop-Helix Motifs | 4 | 1.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/metabolism | 8 | 61.0 |
Isoenzymes/*biosynthesis/metabolism | 2 | 40.0 |
Smoke/*adverse effects | 3 | 15.0 |
RNA, Messenger/analysis/metabolism | 2 | 1.0 |
Turkey/epidemiology | 3 | 4.0 |
Liver/*drug effects/enzymology/metabolism | 2 | 28.0 |
Micronuclei, Chromosome-Defective | 2 | 18.0 |
Placenta/*enzymology | 4 | 5.0 |
DNA/biosynthesis | 2 | 0.0 |
Reproducibility of Results | 6 | 0.0 |
Carcinoma, Squamous Cell/enzymology/genetics | 2 | 25.0 |
Alcohol Drinking/adverse effects | 2 | 4.0 |
Recombinant Proteins/biosynthesis/metabolism | 3 | 1.0 |
Isoenzymes/genetics/*metabolism | 3 | 3.0 |
Breast/cytology/drug effects/*metabolism | 2 | 50.0 |
Antineoplastic Agents, Hormonal/*metabolism | 2 | 50.0 |
Estrogen Antagonists/*metabolism | 2 | 33.0 |
Tamoxifen/*metabolism | 2 | 22.0 |
Embryonic and Fetal Development | 2 | 0.0 |
Isoenzymes/biosynthesis/genetics/*metabolism | 2 | 22.0 |
Xenobiotics/adverse effects/*metabolism | 2 | 100.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
Age Distribution | 3 | 0.0 |
Creatinine/urine | 2 | 1.0 |
Police | 2 | 66.0 |
Sex Distribution | 2 | 0.0 |
Cytochrome P-450 CYP1A1/blood/*genetics | 2 | 100.0 |
Cytochrome P-450 Enzyme System/*drug effects | 2 | 15.0 |
Glycyrrhizic Acid/*pharmacology | 2 | 40.0 |
Smoking/metabolism | 3 | 5.0 |
Probability | 4 | 0.0 |
Xenobiotics/*pharmacokinetics | 2 | 12.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
Drug Evaluation, Preclinical/methods | 2 | 6.0 |
Cytochrome P-450 Enzyme System/biosynthesis | 4 | 21.0 |
Indoles/*pharmacology | 3 | 3.0 |
Oxidoreductases/biosynthesis | 3 | 75.0 |
Quinolines/*metabolism | 2 | 11.0 |
Glutathione Transferase/*biosynthesis | 2 | 20.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
Verapamil/pharmacology | 2 | 2.0 |
Consensus Sequence | 2 | 0.0 |
Cytochrome P-450 CYP1A1/*biosynthesis/*genetics | 3 | 100.0 |
Lung/enzymology | 2 | 3.0 |
Macrophages, Alveolar/*enzymology | 2 | 22.0 |
Saccharomyces cerevisiae/metabolism | 2 | 1.0 |
Gene Expression Regulation, Enzymologic/*drug effects/genetics | 2 | 40.0 |
Particle Size | 3 | 1.0 |
Promoter Regions (Genetics)/*genetics | 4 | 0.0 |
Cytochrome P-450 CYP2D6/*metabolism | 3 | 8.0 |
Hypnotics and Sedatives/*metabolism | 2 | 28.0 |
Isoenzymes/antagonists & inhibitors/*metabolism | 2 | 5.0 |
Isoenzymes/*physiology | 2 | 6.0 |
Glucuronosyltransferase/*biosynthesis/genetics | 2 | 22.0 |
Molecular Conformation | 2 | 0.0 |
*Nerve Tissue Proteins | 2 | 0.0 |
Enhancer Elements (Genetics) | 5 | 1.0 |
Polychlorinated Biphenyls/pharmacology | 3 | 37.0 |
Polycyclic Hydrocarbons, Aromatic/*pharmacology | 4 | 66.0 |
Receptors, Aryl Hydrocarbon/chemistry/*genetics/metabolism | 2 | 66.0 |
Cytochrome P-450 Enzyme System/immunology/*metabolism | 3 | 20.0 |
Prodrugs/*pharmacokinetics | 2 | 18.0 |
Recombinant Proteins/immunology/metabolism | 2 | 4.0 |
Carcinoma, Basal Cell/*epidemiology/genetics | 2 | 100.0 |
Macromolecular Substances | 3 | 0.0 |
Nuclear Proteins/*metabolism | 3 | 0.0 |
Cell Culture Techniques/*methods | 2 | 2.0 |
Linoleic Acid | 2 | 7.0 |
Lung Neoplasms/enzymology/*etiology | 2 | 100.0 |
Chlorzoxazone/metabolism | 2 | 10.0 |
Keratinocytes/metabolism | 3 | 2.0 |
Intestinal Mucosa/cytology/*enzymology | 2 | 33.0 |
Arylamine N-Acetyltransferase/metabolism | 2 | 9.0 |
Cytochrome P-450 Enzyme System/genetics/immunology/*metabolism | 2 | 33.0 |
NAD(P)H Dehydrogenase (Quinone)/genetics | 2 | 11.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/biosynthesis | 4 | 36.0 |
Cytochrome P-450 CYP1A1/biosynthesis/metabolism | 2 | 40.0 |
Superoxide Dismutase/*genetics | 5 | 2.0 |
*Gene Expression Regulation/drug effects | 2 | 1.0 |
Methoxychlor/*metabolism | 2 | 40.0 |
Cytochrome P-450 Enzyme System/genetics/*physiology | 2 | 18.0 |
*Variation (Genetics) | 4 | 0.0 |
Choriocarcinoma | 2 | 5.0 |
Receptors, Aryl Hydrocarbon/chemistry/*genetics | 2 | 66.0 |
Epithelial Cells | 2 | 0.0 |
Benzimidazoles/*pharmacology | 3 | 13.0 |
Omeprazole/analogs & derivatives/pharmacology | 3 | 60.0 |
Gene Expression Regulation/*genetics | 2 | 1.0 |
*Individuality | 2 | 33.0 |
Quinone Reductases/genetics | 2 | 28.0 |
*Exons | 3 | 0.0 |
Enzyme Inhibitors/*metabolism | 2 | 2.0 |
Cell Division/physiology | 3 | 0.0 |
Transformation, Genetic | 4 | 2.0 |
Liver/*drug effects/*enzymology | 4 | 50.0 |
Luciferases/genetics | 2 | 0.0 |
Otorhinolaryngologic Neoplasms/*genetics | 2 | 66.0 |
Gene Amplification | 2 | 0.0 |
Lung Neoplasms/enzymology/*etiology/genetics | 2 | 33.0 |
England | 2 | 1.0 |
Longitudinal Studies | 2 | 0.0 |
Warfarin/pharmacology | 2 | 13.0 |
Coturnix | 2 | 8.0 |
Liver/cytology/*drug effects/embryology/enzymology | 2 | 100.0 |
Liver Neoplasms/pathology | 2 | 4.0 |
*Phenotype | 2 | 0.0 |
Amino Acids/chemistry | 2 | 1.0 |
Kidney/metabolism | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis/*methods | 3 | 2.0 |
Plant Extracts/chemistry/pharmacology | 2 | 20.0 |
Methyltransferases/genetics | 2 | 11.0 |
China | 5 | 1.0 |
Cytochrome P-450 CYP1A2 | 11 | 12.0 |
Cytochrome P-450 Enzyme System/*immunology | 2 | 28.0 |
Xenobiotics/*toxicity | 2 | 20.0 |
beta-Naphthoflavone | 7 | 38.0 |
Glucuronosyltransferase/genetics/metabolism | 3 | 23.0 |
Hepatocytes/*drug effects/enzymology | 3 | 21.0 |
MAP Kinase Signaling System/drug effects | 2 | 2.0 |
Mitogen-Activated Protein Kinases/*antagonists & inhibitors/metabolism | 3 | 21.0 |
Leukocyte Count | 2 | 0.0 |
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide/*pharmacology | 2 | 40.0 |
Lung Neoplasms/pathology | 2 | 3.0 |
Arachidonic Acid/*metabolism | 2 | 5.0 |
Oligonucleotide Probes | 3 | 0.0 |
Temperature | 2 | 0.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Anticarcinogenic Agents/*therapeutic use | 2 | 10.0 |
Environmental Pollutants | 2 | 40.0 |
Isoenzymes | 3 | 1.0 |
Polychlorinated Biphenyls/*toxicity | 2 | 12.0 |
Cytochrome P-450 CYP2E1 | 6 | 5.0 |
Oxazines/chemistry/*metabolism | 2 | 100.0 |
*Occupational Health | 2 | 14.0 |
Cell Adhesion | 3 | 0.0 |
Microspheres | 2 | 1.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*physiology | 2 | 13.0 |
Mixed Function Oxygenases/biosynthesis/*genetics | 2 | 18.0 |
Oxidoreductases/biosynthesis/*genetics | 2 | 66.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
African Continental Ancestry Group | 2 | 0.0 |
Genetics, Population | 4 | 1.0 |
Oxidoreductases/*biosynthesis | 4 | 50.0 |
Keratinocytes/*enzymology | 2 | 22.0 |
DNA, Complementary/*genetics | 4 | 1.0 |
Recombinant Proteins/genetics/isolation & purification/metabolism | 2 | 2.0 |
Carcinogens/*pharmacology | 3 | 4.0 |
Epoxide Hydrolases/genetics/*metabolism | 3 | 60.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/*genetics | 5 | 45.0 |
Oligodeoxyribonucleotides | 3 | 0.0 |
Steroid Hydroxylases/*biosynthesis | 2 | 40.0 |
Continental Population Groups/*genetics | 2 | 4.0 |
Benz(a)Anthracenes/*pharmacology | 2 | 100.0 |
*Models, Genetic | 2 | 1.0 |
Oxidoreductases/genetics/metabolism | 5 | 41.0 |
Theophylline/*metabolism | 2 | 40.0 |
Uric Acid/analogs & derivatives/metabolism | 2 | 50.0 |
Trans-Activators/metabolism | 2 | 0.0 |
Xenobiotics/pharmacology | 3 | 13.0 |
P-Glycoprotein/*genetics | 2 | 4.0 |
Brazil | 4 | 1.0 |
Serine/metabolism | 2 | 0.0 |
Colon/enzymology | 2 | 7.0 |
Sulfotransferases/metabolism | 2 | 14.0 |
Pharmacogenetics | 2 | 1.0 |
Lung/*metabolism/pathology | 2 | 9.0 |
Xenobiotics/metabolism/*pharmacology | 2 | 50.0 |
Deoxyribonucleases, Type II Site-Specific | 2 | 0.0 |
Breast Neoplasms/pathology | 3 | 2.0 |
Aryl Hydrocarbon Hydroxylases/analysis | 2 | 50.0 |
Cytochrome P-450 Enzyme System | 2 | 40.0 |
Lung Neoplasms/enzymology/genetics | 2 | 20.0 |
Breast Neoplasms/*metabolism | 2 | 0.0 |
Oxidoreductases/*biosynthesis/metabolism | 2 | 100.0 |
NAD(P)H Dehydrogenase (Quinone)/biosynthesis/*genetics | 2 | 50.0 |
Tumor Markers, Biological/genetics | 4 | 4.0 |
*Cadmium Compounds | 2 | 50.0 |
*Sulfates | 2 | 40.0 |
Adenocarcinoma/enzymology/genetics | 2 | 10.0 |
Oxidoreductases, N-Demethylating/*biosynthesis/metabolism | 2 | 33.0 |
Molecular Weight | 2 | 0.0 |
Recombinant Proteins | 3 | 0.0 |
DNA/*metabolism | 4 | 0.0 |
Cell Size | 2 | 0.0 |
Benzofurans/*metabolism | 2 | 66.0 |
Tetrachlorodibenzodioxin/*metabolism | 2 | 28.0 |
RNA-Directed DNA Polymerase/metabolism | 3 | 4.0 |
Aryl Hydrocarbon Hydroxylases/*antagonists & inhibitors | 2 | 12.0 |
Methylcholanthrene/*metabolism | 2 | 100.0 |
*Genes, Structural | 2 | 0.0 |
Aldehyde Dehydrogenase/biosynthesis/*genetics | 2 | 40.0 |
Epoxy Compounds/metabolism | 2 | 25.0 |
Oxidoreductases/*analysis | 2 | 25.0 |
Carcinogens, Environmental/toxicity | 2 | 33.0 |
Dioxins/*toxicity | 2 | 20.0 |
Polymorphism, Single Nucleotide/*genetics | 3 | 1.0 |
Receptors, Aryl Hydrocarbon | 3 | 18.0 |
Genetic Vectors/genetics | 2 | 0.0 |
Carcinoma, Squamous Cell/epidemiology/*genetics | 4 | 23.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/*metabolism | 2 | 7.0 |
Xenobiotics | 2 | 28.0 |
Fluorometry | 2 | 2.0 |
Enzyme Induction/*drug effects | 3 | 17.0 |
Insects | 2 | 1.0 |
Microsomes, Liver | 2 | 20.0 |
Neoplasms/*chemically induced/genetics | 2 | 66.0 |
Lung Neoplasms/*enzymology/*genetics | 2 | 16.0 |
NAD(P)H Dehydrogenase (Quinone)/genetics/metabolism | 2 | 66.0 |
Glucuronosyltransferase/genetics | 2 | 12.0 |
Cytochrome P-450 CYP1A1/*genetics/pharmacology | 2 | 100.0 |
Aromatase/genetics | 3 | 21.0 |
p38 Mitogen-Activated Protein Kinases | 2 | 0.0 |
JNK Mitogen-Activated Protein Kinases | 2 | 0.0 |
Tandem Repeat Sequences | 2 | 1.0 |
Occupational Exposure/adverse effects/*analysis | 2 | 40.0 |
Polycyclic Hydrocarbons, Aromatic/adverse effects/*analysis | 2 | 66.0 |
Pyridines/metabolism/*pharmacology | 2 | 100.0 |
5' Flanking Region/genetics | 2 | 2.0 |
Aryl Hydrocarbon Hydroxylases/biosynthesis/genetics | 2 | 28.0 |
Cytochrome P-450 CYP1A2/biosynthesis/genetics | 2 | 100.0 |
RNA, Messenger/biosynthesis/isolation & purification | 2 | 9.0 |
Vehicle Emissions/*toxicity | 2 | 25.0 |
Isoenzymes/biosynthesis/genetics | 2 | 4.0 |
Stilbenes/pharmacology | 2 | 6.0 |
Esophageal Neoplasms/epidemiology/*genetics | 2 | 25.0 |
Adenocarcinoma/epidemiology/*genetics | 3 | 30.0 |
Cytochrome P-450 CYP2E1/biosynthesis | 2 | 66.0 |
Reverse Transcriptase Polymerase Chain Reaction/*methods | 3 | 5.0 |
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors/*biosynthesis | 2 | 66.0 |
Cytochrome P-450 CYP2D6/genetics/metabolism | 2 | 13.0 |
Biological Availability | 2 | 0.0 |
Spectrum Analysis, Mass/methods | 2 | 5.0 |
Cytochrome P-450 CYP1A1/antagonists & inhibitors/*biosynthesis | 2 | 100.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors/*biosynthesis | 2 | 100.0 |
Tryptophan/metabolism | 2 | 8.0 |
Gene Expression Regulation, Enzymologic/drug effects/physiology | 2 | 6.0 |
DNA/*drug effects/metabolism | 2 | 28.0 |
Africa | 2 | 2.0 |
